Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
3(75.0%)
Phase 4
1(25.0%)
4Total
Phase 3(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT02635334Phase 4Completed

Asthma in the Elderly: The Effect of Montelukast

Role: lead

NCT00939354Completed

Asthma in the Elderly: The Role of Exhaled Nitric Oxide Measurements

Role: lead

NCT02371993Phase 3Completed

Asthma in the Elderly: A Study of Choline Supplementation

Role: lead

NCT01318954Completed

The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Patients With Asthma and Allergic Rhinitis

Role: lead

NCT02272101Phase 3Completed

Rhinitis in the Elderly: The Role of Vitamin D

Role: lead

NCT01730976Phase 3Completed

Asthma in the Elderly: The Role of Vitamin D

Role: lead

All 6 trials loaded